Thermo Fisher to Present at Morgan Stanley’s Global Healthcare Conference on September 15

Thermo Fisher Scientific (NYSE: TMO) announced that it will present at the Morgan Stanley 24th Annual Global Healthcare Conference scheduled for September 15, 2026. This participation provides the company with a key opportunity to engage directly with investors and analysts ahead of its next earnings cycle, signaling management’s intent to discuss business trajectory and strategic priorities in diagnostics and life‑sciences.

The conference presentation follows closely on the heels of Thermo Fisher’s second-quarter 2026 earnings report, delivered on July 23, in which the company reported 10% revenue growth to $11.99 billion and a 13% increase in adjusted EPS to $6.03 for the quarter ended June 27. Management highlighted new product launches, including AI‑enabled Orbitrap mass spectrometers and the Applied Biosystems PowerFlex thermal cycler, plus a strategic collaboration to support Singapore’s PRECISE‑SG100K population health study, and the divestiture of its microbiology business alongside a $1 billion share repurchase program. These developments underscore the company’s emphasis on precision diagnostics, innovation, and capital discipline.

Attending the Morgan Stanley conference affords Thermo Fisher a platform to elaborate on these initiatives, convey forward guidance, and reinforce its role in powering scientific and diagnostic platforms amid evolving R&D dynamics. Investors will be watching for commentary on diagnostic market momentum, post‑divestiture capital allocation, and order‑book trends in life‑sciences and clinical markets.

With Thermo Fisher’s stock price confirmed at $609.82, down slightly by 0.02% as of September 11, 2026, the upcoming presentation may catalyze renewed investor interest. While no direct causation between the announcement and the stock’s movement has been established, the event represents a timely chance for management to shape market expectations and investor sentiment as the company navigates growth execution.

Looking ahead, key points to monitor include any updated guidance or near‑term outlook shared at the conference, commentary on end‑market demand trends, and the company’s deployment of capital post‑microbiology‑unit sale. The presentation could set the tone for Thermo Fisher’s fourth‑quarter trajectory and provide clarity ahead of its next earnings release.